RNS Number : 9285W
Renishaw PLC
13 February 2025
 

Renishaw plc        

 

13 February 2025

 

Interim report for the six months ended 31 December 2024 (H1 FY2025)

 

Steady progress in H1 with demand picking up at the start of H2

 

 

6 months to

31 December

2024

 

6 months to

31 December

2023

Change (%)

 

Revenue (£m)

341.4

330.5

                      +3


 



Profit before tax* (£m)

57.5

56.5

+2


 



Operating profit* (£m)

51.6

47.2

+9


 



Earnings per share* (pence)

63.2

62.1

+2


 



Dividend per share (pence)

16.8

16.8

-


 



Adjusted* cash flow from operating activities (£m)

51.5

22.9

+125

 

 



 

 

Performance highlights

 

1.  H1 FY2025 revenue 3% higher at £341.4m (H1 FY2024: £330.5m):

·    2% revenue growth at constant exchange rates*, excluding impact of forward contracts;

·    Growth in Americas and EMEA, lower revenue in APAC;

·    Manufacturing technologies up 4% at £322.6m, with growth from Position Measurement and Additive Manufacturing products, weaker demand from machine builders for Industrial Metrology products; and

·    Analytical instruments and medical devices 3% lower at £18.8m, with growth in Neurological products offset by lower Spectroscopy sales.

2.  Profit before tax 2% higher at £57.5m (H1 FY2024: £56.5m):

·    Gross margin excluding engineering costs improved by 1.0% to 61.5%;

·    Operating profit up 9% at £51.6m at actual exchange rates, down 5% at constant currency; and

·    Profit before tax in Q2 was lower than Q1 due to less favourable currency contracts, adverse product mix, and one-off supply chain costs.

3.  Adjusted* cash flow conversion from operating activities above target at 100%, reflecting strong operating cash flows and planned lower capital expenditure:

·    Strong balance sheet, with cash and cash equivalents and bank deposit balances of £233.2m (30 June 2024: £217.8m).

4.  Continued progress on our strategic priorities, with new product launches in H1 that strengthen our position in established and emerging markets.

5.  Interim dividend of 16.8 pence per share.

6.  Outlook:

·      Order intake recently improved, steady revenue growth expected to continue in H2;

·      FY2025 revenue range:                    Â£695m to £735m; and

·      FY2025 adjusted profit before tax:   £105m to £135m.

 

* For this period and the comparable period there is no difference between 'Statutory' and 'Adjusted' for some of our alternative performance measures, being Adjusted profit before tax, Adjusted earnings per share and Adjusted operating profit. Note 12, Alternative performance measures, defines how other alternative measures are calculated.


Will Lee, Chief Executive, commented:

"We have continued to make steady progress in mixed trading conditions and our order intake has recently improved, particularly from the semiconductor manufacturing and consumer electronics sectors. Supported by our strategic progress, we expect to achieve steady revenue growth this year. Our markets present significant structural growth opportunities, and we are confident that the investment that we are currently making in productivity improvements will drive our operating margins towards our 20% target in the medium term."

 

 

About Renishaw

 

We are a world leading supplier of measuring and manufacturing systems. Our products give high accuracy and precision, gathering data to provide customers and end users with traceability and confidence in what they are making. This technology also helps our customers to innovate their products and processes. We are a global business, with customer-facing locations across our three sales regions; the Americas, EMEA, and APAC. Most of our R&D work takes place in the UK, with our largest manufacturing sites located in the UK, Ireland and India.

 

Further information can be found at www.renishaw.com

 

Results presentation

 

See below a video presentation of these results, presented by Will Lee, Chief Executive, and Allen Roberts, Group Finance Director.  

  

Your browser does not support HTML5 video.


Live Q&A session

There will be a live audio-only question and answer session with Will and Allen at 10:30 GMT on 13 February 2025. Details of how to register for this webcast are available at the following link: 

https://www.renishaw.com/en/register-for-the-2025-interim-results-webcast--49582

Questions can be submitted in advance of the webcast to communications@renishaw.com (please submit by 9:30 GMT on 13 February).


A recording of the Q&A session will be made available by 14 February 2025 at:
www.renishaw.com/investors.

 

Enquiries: communications@renishaw.com



 

Overview for the six months ended 31 December 2024

 

Revenue

Revenue for the six months ended 31 December 2024 was £341.4m, 3% higher than £330.5m for the corresponding period last year. Manufacturing technologies revenue increased by 4%, with growth in Position Measurement (PM) and Additive Manufacturing (AM) products and weaker demand from machine builders for Industrial Metrology (IM) products. Analytical instruments and medical devices revenue was 3% lower, with growth in Neurological products being offset by lower demand for Spectroscopy products.

 

At constant currency*, Group revenue increased by 2%. APAC revenue was down 1% at constant currency, with weaker sales of IM products to the consumer electronics sector, although orders from these customers have recently improved.  By contrast, sales of position encoders to semiconductor equipment manufacturers rose during the period, also supported by a strengthening order book.  EMEA revenue was 5% higher at constant currency, with strong growth in co-ordinate measuring machine (CMM) systems, AM systems and position encoders, but weaker demand for IM sensors from machine builders. Americas revenue also grew by 5% at constant currency, with growth in AM systems and position encoders, and also has an improved order book.

 

 

6 months to

31 December

2024

6 months to

31 December

2023

Change %

Constant fx* change %

Group revenue

£341.4m

£330.5m

+3%

+2%

Comprising:





   APAC

£161.4m

£161.2m

+0%

-1%

   EMEA

£102.3m

£97.2m

+5%

+5%

   Americas

£77.7m

£72.1m

+8%

+5%

 

New product introductions and commercialisation

We have made progress during the first six months of the financial year in each of our three strategic priorities:

1.     Growing in our existing markets - aiming to increase revenue by driving up probe fitment levels, offering usable and higher value sensors, and by winning more machine builder customers. 

·  Enhanced the usability of our twin probe system for machine tools, introducing patented Opti-Logicâ„¢ technology for fast set-up using a smartphone app.

·  Launched enhancements to our range of modular metrology fixtures, improving ease-of-use and reducing environmental impact.

·   Continued to win new customers and grow revenue from our FORTiSâ„¢ enclosed position encoders, now featuring longer axis lengths for larger machine tools.  

2.     Increasing the value of the technology we sell - aiming to provide our end-user customers with complete solutions to capture a greater proportion of their investment.

·  Launched the RenAM 500D dual laser AM machine, featuring our patented TEMPUSâ„¢ technology, offering production speeds up to three times faster than conventional single laser systems.   

·  Added five new processable materials for our AM machines and new powder layer thicknesses for existing materials.   

3.     Extending into new, high-growth markets - aiming to diversify into close-adjacent markets where we have strong market understanding and brand awareness.

·  Launched our new ASTRiAâ„¢ inductive encoder line, offering robust and accurate position measurement in demanding environments, including robotics, defence and medical devices.

 

Operating profit and costs

 

Operating profit for the period was £51.6m, a 9.3% increase on the previous period. This amounts to 15% of revenue, against 14% last year, and against our target of 20%. The current period includes significant gains from forward currency contracts, which were entered into at favourable rates following volatility in currency markets arising from the September 2022 UK 'mini Budget'. These benefits were mostly experienced in Q1. When excluding these, and translating H1 FY2025 results at FY2024 exchange rates, operating profit at constant exchange rates* was 4.9% lower than the previous year.

 

Labour costs have increased by £9.6m compared to the prior financial year. This increase primarily results from January 2024 salary reviews, plus a net headcount increase of 98 (which mostly relates to graduates and apprentices). Our salary review in January 2025 amounted to around 4% of our total labour costs, which will increase our labour costs in the second half of the financial year by around £7m. While we will continue to invest in employee remuneration to ensure competitiveness and retention of highly skilled and trained employees, our recruitment plans will also need to consider the impact of the UK Government's October 2024 Budget, which is expected to increase FY2025 labour costs by £1m and will add £4m to our annual costs.

 

Our gross margin (excluding engineering costs) for the period was 61.5% of revenue, an improvement of 1% over the comparable period in the previous year. Within this gross margin, we have seen favourable variances relating to currency and component purchase costs, however these have been partly offset by continued pricing pressures, particularly in the APAC region. We have also experienced a specific supply chain quality issue during Q2, which has resulted in around £2m of non-recurring costs.  This impacted the pace of product shipments in the period, which we expect to catch up in H2.

 

We remain committed to our long-term strategy of developing innovative and patented products to create strong market positions. During the first six months of this financial year, our gross engineering spend, including research and development, increased by 8% to £55.5m. This increase mostly related to labour costs, and includes £1.4m of severance costs relating to the closure of a research site in Edinburgh, UK.

 

We have controlled distribution and administrative expenses, with no significant year-on-year increase at actual exchange rates. This includes further increases in third-party support and maintenance costs in relation to our ongoing IT transformation, which will lead to productivity benefits in future years.

 

Profit and tax

Financial income less expenses for the period was £4.1m compared with £6.8m last year. While interest on bank deposits increased by £1.3m, we have experienced £1.7m of currency losses (FY2024 H1: £1.0m gain) on intragroup financing balances and mitigating forward currency swap contracts.

 

The resulting profit before tax for the period was £57.5m (17% of revenue) compared with £56.5m (17% of revenue) last financial year. In previous reporting periods, we have reported adjusted profit measures. For this period and the comparable period there are no adjusting items, and therefore adjusted and statutory profit measures are equivalent.

 

The income tax expense in the Consolidated income statement has been estimated at a rate of 20.1% (H1 FY2024: 20.1%) and is based on management's best estimate of the full year effective tax rates by geographical unit applied to half-year profits. This compares to 21.0% in FY2024.

 

Earnings per share were 63.2p, compared with 62.1p last year.

 

Operating profit for our Manufacturing technologies segment, which comprises our Industrial Metrology, Position Measurement and Additive Manufacturing products, was £52.8m for the first six months, compared with £46.0m for the same period in the last financial year.  Our Analytical Instruments and medical devices segment, which comprises our Spectroscopy and Neurological products, made a loss of £1.2m in the first six months compared with a profit of £1.2m for the same period in the last financial year.

 

Cash flow

In working capital, our trade receivables have reduced by £21.5m, in line with the profile of our quarterly revenue and with minimal movement in debtor days, while we continue to carefully manage our inventory balances, which have reduced by £4.2m to £157.8m.  

 

We have reduced our planned capital expenditure during the period following the significant investment in our manufacturing facility in Wales over the previous two years. The first of the two new halls became operational in FY2024, which provides additional production capacity for our physically larger products including CMMs, additive manufacturing machines and enclosed encoders.

 

As a result, we have achieved strong adjusted* cash flow conversion from operating activities of 100%, which is above our target of 70%. Cash and cash equivalents and bank deposit balances at 31 December 2024 were £233.2m, compared with £217.8m at 30 June 2024, primarily reflecting cash generated from operating activities of £76.2m, less capital expenditure of £23.4m, and the final dividend payment of £43.2m in respect of FY2024.

 

Dividend

The Board has approved an interim dividend of 16.8p net per share (FY2024: 16.8p), which will be paid on 8 April 2025 to shareholders on the register on 7 March 2025.

 

Principal risks and uncertainties

The Board has considered the risks and uncertainties which could have a material effect on the Group's

performance and position. While there is heightened uncertainty arising from geopolitical matters and trade

tensions, these have not yet impacted our business, and the Board continues to monitor the situation closely. The overall impact and likelihood of our other principal risks is not considered to have changed

significantly. This conclusion also reflects the mitigation undertaken by the Group in response to these

risks. The principal risks and uncertainties set out on pages 11 to 18 of the 2024 Annual Report therefore

remain relevant.

 

Sustainability

We continue to make strong progress towards our target of Net Zero for Scopes 1 and 2 emissions by 2028. During the period, we have started work on converting heating systems at our facility in Pliezhausen, Germany, from oil to a lower-carbon alternative. We are also focused on reducing our Scope 3 emissions, including working with key suppliers to reduce the carbon impact of the materials that we use to make our products.  Last year we increased the recycled content of our raw aluminium supply, generating annual savings of 3,000 tonnes of CO2, and are now working on further supply chain savings with other suppliers and materials.

 

We continue to see significant commercial opportunities arising from the drive towards sustainable business practices. Our products help our customers to meet their sustainability targets by increasing their manufacturing efficiencies through lower energy consumption and waste, and also by improving the performance of the products they supply to their own customers.

 

Sir David McMurtry

In December 2024, it was with profound sadness that we announced the death of our co-founder and Non-executive Director, Sir David McMurtry. We have since been overwhelmed by messages of support from around the world. People reflected on David's role as a visionary and empathetic business leader, as a passionate innovator, how he shaped an entire industry, and also his decency, humility and great sense of humour. Whilst his presence is deeply missed, the ethos that he and John Deer instilled in Renishaw continues to guide us. 

 

Directors and employees

The Directors would like to thank our employees for continuing to drive us forward towards our vision to innovate and transform the capabilities of our customers.

 

Sir David McMurtry's son, Richard McMurtry, joined the Board as a Non-executive Director in July 2024. The Renishaw Board is working to appoint an Independent Non-executive Chair whilst continuing work on succession planning, including additional Non-executive Director recruitment.

 

Outlook

The Board remains confident in our growth model, built on solving customer problems with innovative products, global service and world-class in-house manufacturing. Whilst we operate in cyclical markets, we aim for high single-digit average organic growth rates through the cycle, to improve our operating profit margins to above 20%, and to generate strong free cash flow. 

 

We have continued to make steady progress in mixed trading conditions and our order intake has recently improved, particularly from the semiconductor manufacturing and consumer electronics sectors. Supported by our strategic progress, we expect to achieve steady revenue growth this year. Our markets present significant structural growth opportunities, and we are confident that the investment that we are currently making in productivity improvements will drive our operating margins towards our 20% target in the medium term.

 

At this stage we expect full year revenue to be in the range of Â£695m to £735m. Adjusted profit before tax is expected to be in the range of £105m to £135m.

 

 

Will Lee

Allen Roberts

Chief Executive

Group Finance Director

 

 

12 February 2025

 

 

 

* For this period and the comparable period there is no difference between 'Statutory' and 'Adjusted' for some of our alternative performance measures, being Adjusted profit before tax, Adjusted earnings per share and Adjusted operating profit. Note 12, Alternative performance measures, defines how other alternative measures are calculated.

 

Consolidated income statement

 

 

 

 

 

from continuing operations

 

 

 

 

Notes

 

Unaudited

6 months to

31 December

2024

£'000

 

Unaudited

6 months to

31 December

2023

£'000

 

Audited

Year ended

30 June

2024

£'000

 

Revenue

2

341,402

330,489

691,301






Cost of sales

3

(182,060)

(175,904)

(367,658)






Gross profit


159,342

154,585

323,643






Distribution costs


(68,276)

(68,871)

(139,901)

Administrative expenses


(39,506)

(38,520)

(75,075)






Operating profit


51,560

47,194

108,667






Financial income

4

6,339

7,168

12,336

Financial expenses

4

(2,221)

(351)

(2,289)

Share of profits from joint ventures


1,806

2,530

3,880






Profit before tax


57,484

56,541

122,594






Income tax expense

5

(11,555)

(11,364)

(25,705)






Profit for the period


45,929

45,177

96,889






Profit attributable to:





Equity shareholders of the parent company


45,929

45,177

96,889

Non-controlling interest


-

-

-

Profit for the period


45,929

45,177

96,889








Pence

Pence

Pence

Dividend per share arising in respect of the period

7

16.8

16.8

76.2






Earnings per share (basic and diluted)

6

63.2

62.1

133.2

 

 

 

 

​

 

Consolidated statement of comprehensive income and expense

 


Unaudited

6 months to

31 December

2024

£'000

Unaudited

6 months to

31 December

2023

£'000

Audited

Year ended

30 June

2024

£'000


 



Profit for the period

45,929

45,177

96,889


 



Other items recognised directly in equity:

 



 

 



Items that will not be reclassified to the Consolidated income statement:

 



Remeasurement of defined benefit pension scheme assets/liabilities

732

(49,459)

(48,688)

Deferred tax on remeasurement of defined benefit pension scheme assets/liabilities

(84)

12,349

12,424


 



Total for items that will not be reclassified

648

(37,110)

(36,264)

 

 



Items that may be reclassified to the Consolidated income statement:

 



Exchange differences in translation of overseas operations

(1,864)

1,576

(4,038)

Exchange differences in translation of overseas joint venture

(528)

159

(311)

Current tax on translation of net investments in foreign operations

-

(297)

57

Effective portion of changes in fair value of cash flow hedges, net of recycling

(11,188)

4,422

5,812

Deferred tax on effective portion of changes in fair value of cash flow hedges

2,839

(1,105)

(1,453)


 



Total for items that may be reclassified

(10,741)

4,755

67


 



Total other comprehensive income and expense, net of tax

(10,093)

(32,355)

(36,197)


 



Total comprehensive income and expense for the period

35,836

12,822

60,692

 




Attributable to:




Equity shareholders of the parent company

35,836

12,822

60,692

Non-controlling interest

-

-

-





Total comprehensive income and expense for the period

35,836

12,822

60,692

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Consolidated balance sheet


 

 

 

Notes

Unaudited

At 31 December

2024

£'000

Unaudited

At 31 December

2023*

£'000

Audited

At 30 June

2024

£'000

Assets





Property, plant and equipment

8

           334,997

318,036

 325,040

Right-of-use assets


              13,773

 10,049

 14,746

Investment properties


              10,076

 10,181

 10,285

Intangible assets

9

              49,224

 48,319

 47,343

Investments in joint ventures


              26,089

 24,529

 25,485

Finance lease receivables

 

              14,430

 8,814

 11,944

Employee benefits

 

              11,410

 9,128

 10,845

Deferred tax assets

 

              17,558

 20,006

 17,690

Derivatives

10

                2,052

 3,233

1,387

Total non-current assets


           479,609

 452,295

 464,765






Current assets





Inventories


           157,758

174,383

 161,928

Trade receivables

10

           112,616

 116,268

 134,073

Finance lease receivables


                3,382

 3,552

 3,861

Current tax


                8,123

13,642

 21,298

Other receivables


              43,756

 37,693

 34,076

Derivatives

10

                5,412

 11,585

 13,547

Bank deposits


           143,000

 119,000

 95,542

Cash and cash equivalents


              90,161

 59,258

 122,293

Total current assets


           564,208

 535,381

586,618






Current liabilities





Trade payables


              23,544

22,011

 21,330

Contract liabilities


              13,806

 7,811

 10,880

Current tax


                2,662

 1,452

 1,767

Provisions


                3,963

 2,722

 2,997

Derivatives

10

                2,385

 1,529

 448

Lease liabilities


                3,915

 3,217

 3,960

Amounts owed to joint ventures

13

              11,570

-

 8,475

Borrowings


                   773

 4,372

 747

Other payables


              40,059

 43,654

 50,344

Total current liabilities


           102,677

 86,768

 100,948

Net current assets


           461,531

 448,613

485,670






Non-current liabilities





Lease liabilities


              10,313

7,083

 11,062

Borrowings


                2,491

 -

 2,775

Employee benefits


                       -  

 90

 -  

Deferred tax liabilities


              30,106

27,007

 33,600

Derivatives

10

                2,520

 -  

 177

Total non-current liabilities


              45,430

 34,180

 47,614

Total assets less total liabilities


           895,710

 866,728

 902,821






Equity





Share capital


              14,558

14,558

 14,558

Share premium


                     42

 42

 42

Own shares held


(2,367)

(2,963)

(2,963)

Currency translation reserve


                     88

 8,210

 2,480

Cash flow hedging reserve


                2,562

 9,869

 10,911

Retained earnings


           880,362

 836,649

 876,990

Other reserve


                1,042

 940

 1,380

Equity attributable to the shareholders of the parent company


           896,287

 867,305

 903,398

Non-controlling interest


(577)

(577)

(577)

Total equity


           895,710

 866,728

 902,821

 

* December 2023 Other receivables have been reclassified to include Contract assets.



Consolidated statement of changes in equity

 

Unaudited

 

Share

capital

£'000

 

Share

premium

£'000

 

Own

shares

held

£'000

Currency

translation

reserve

£'000

Cash flow

hedging

reserve

£'000

 

Retained

earnings

£'000

 

Other

reserve

£'000

Non-

controlling

interest

£'000

 

 

 

Total

£'000

 

Balance at 1 July 2023

14,558

42

(2,963)

6,772

6,552

871,777

497

(577)

896,658











Profit for the period

-

-

-

-

-

45,177

-

-

45,177











Other comprehensive income and expense (net of tax)










Remeasurement of defined benefit pension assets/liabilities

-

-

-

-

-

(37,110)

-

-

(37,110)

Foreign exchange translation differences

-

-

-

1,279

-

-

-

-

1,279

Relating to joint ventures

-

-

-

159

-

-

-

-

159

Changes in fair value of cash flow hedges

-

-

-

-

3,317

-

-

-

3,317

Total other comprehensive income and expense

-

-

-

1,438

3,317

(37,110)

-

-

(32,355)

Total comprehensive income and expense

-

-

-

1,438

3,317

8,067

-

-

12,822











Transactions with owners recorded in equity










Share-based payments charge

-

-

-

-

-

-

443

-

443

Own shares purchased

-

-

-

-

-

-

-

-

-

Dividends paid

-

-

-

-

-

(43,195)

-

-

(43,195)

Balance at 31 December 2023

14,558

42

(2,963)

8,210

9,869

836,649

940

(577)

866,728











Profit for the period

-

-

-

-

-

51,712

-

-

51,712











Other comprehensive income and expense (net of tax)










Remeasurement of defined benefit pension assets/liabilities

-

-

-

-

-

846

-

-

846

Foreign exchange translation differences

-

-

-

(5,260)

-

-

-

-

(5,260)

Relating to joint ventures

-

-

-

(470)

-

-

-

-

(470)

Changes in fair value of cash flow hedges

-

-

-

-

1,042

-

-

-

1,042

Total other comprehensive income and expense

-

-

-

(5,730)

1,042

846

-

-

(3,842)

Total comprehensive income and expense

-

-

-

(5,730)

1,042

52,558

-

-

47,870











Transactions with owners recorded in equity










Share-based payments charge

-

-

-

-

-

-

440

-

440

Dividends paid

-

-

-

-

-

(12,217)

-

-

(12,217)

Balance at 30 June 2024

14,558

42

(2,963)

2,480

10,911

876,990

1,380

(577)

902,821


 

 

 

 

 

 

 

 

 

Profit for the period

-

-

-

-

-

45,929

-

-

45,929











Other comprehensive income and expense (net of tax)










Remeasurement of defined benefit pension assets/liabilities

-

-

-

-

-

648

-

-

648

Foreign exchange translation differences

-

-

-

(1,864)

-

-

-

-

(1,864)

Relating to joint ventures

-

-

-

(528)

-

-

-

-

(528)

Changes in fair value of cash flow hedges

-

-

-

-

(8,349)

-

-

-

(8,349)

Total other comprehensive income and expense

-

-

-

(2,392)

(8,349)

648

-

-

(10,093)

Total comprehensive income and expense

-

-

-

(2,392)

(8,349)

46,577

-

-

35,836











Transactions with owners recorded in equity










Share-based payments charge

-

-

-

-

-

-

412

-

412

Distribution of own shares

-

-

750

-

-

-

(750)

-

-

Purchase of own shares

-

-

(154)

-

-

-

-

-

(154)

Dividends paid

-

-

-

-

-

(43,205)

-

-

(43,205)

Balance at 31 December 2024

14,558

42

(2,367)

88

2,562

880,362

1,042

(577)

895,710

 

 

Consolidated statement of cash flow


Unaudited

6 months to

31 December

2024

£'000

Unaudited

6 months to

31 December

2023

£'000

Audited

Year ended

30 June

2024

£'000

Cash flows from operating activities




Profit for the period

             45,929

45,177

         96,889

Adjustments for:

 



Depreciation of property, plant and equipment, right-of-use assets, and investment properties

12,278

              11,506

24,195

Profit on sale of property, plant and equipment

(1,005)

(29)

(1,199)

Amortisation and impairment of intangible assets

               2,394

               2,888

             8,633

Share of profits from joint ventures

(1,806)

(2,530)

(3,880)

Defined benefit pension scheme past service and administrative costs

                  494

                  397

             907

Financial income

(6,339)

(7,168)

(12,336)

Financial expenses

                  2,221

                  351

2,289

Share based payment expense

                  412

                  445

                883

Tax expense

             11,555

             11,364

           25,705


             20,204

             17,224

45,197

Decrease in inventories

4,170

             11,374

23,829

Decrease/(increase) in trade and other receivables

8,337

486

(23,719)

Increase/(decrease) in trade and other payables

(5,101)

(6,381)

3,557

Increase/(decrease) in provisions

966

(36)

239


8,372

        5,443

3,906

Defined benefit pension scheme contributions

(79)

(83)

(161)

Income taxes received/(paid)

1,815

(12,191)

(21,752)

Cash flows from operating activities

76,241

             55,350

124,079


 


 

Investing activities

 


 

Purchase of property, plant and equipment, and investment properties

(23,352)

(40,443)

(65,518)

Sale of property, plant and equipment

2,814

                  200

4,475

Development costs capitalised

(4,079)

(4,542)

(9,281)

Purchase of other intangibles

                  (226)

                  (30)

(246)

(Increase)/decrease in bank deposits

 (47,458)

               6,000

29,458

Interest received

               6,091

               4,745

9,110

Dividend received from joint venture

                  674

                  573

498

Cash flows from investing activities

(65,536)

(33,497)

(31,504)


 


 

Financing activities

                       

                       

 

Repayment of borrowings

(390)

(393)

(799)

Amounts received as deposit from joint venture

3,361

-

8,475

Interest paid

(491)

(351)

(608)

Repayment of principal of lease liabilities

(2,069)

(2,607)

(4,359)

Own shares purchased

 (154)  

                     -  

-

Dividends paid

(43,205)

(43,195)

(55,412)

Cash flows from financing activities

(42,948)

(46,546)

(52,703)


 


 

Net (decrease)/increase in cash and cash equivalents

(32,243)

(24,473)

39,872

Cash and cash equivalents at the beginning of the period

122,293

81,388

81,388

Effect of exchange rate fluctuations on cash held

111

2,343

1,033

Cash and cash equivalents at the end of the period

90,161

59,258

122,293

 

Cash and cash equivalents and bank deposits at 31 December 2024 were £233.2m (30 June 2024: £217.8m).

 

 

 

 

 

 

 

Notes

 

1.         Basis of preparation

 

The Interim report, which includes the condensed consolidated financial statements for the six months ended 31 December 2024, was approved by the Directors on 12 February 2025.

The condensed consolidated financial statements for the six months ended 31 December 2024 were prepared in accordance with International Accounting Standard 34 'Interim Financial Reporting' (IAS 34) as issued by the International Accounting Standards Board and as adopted by the UK. These apply the same accounting policies, presentation and methods of calculation as were applied in the preparation of the Group's consolidated financial statements for the year ended 30 June 2024, except for income taxes which are accrued using the forecast tax rate for the financial year.

The condensed consolidated financial statements included in this Report have not been audited and do not constitute the Group's statutory accounts as defined in section 434 of the Companies Act 2006. The information relating to the year ended 30 June 2024 is an extract from the Group's published Annual Report for that year, which has been delivered to the Registrar of Companies, and on which the auditor's report was unqualified and did not contain any emphasis of matter or statements under section 498(2) or 498(3) of the Companies Act 2006.

Going concern

The Directors have prepared the unaudited interim financial information on a going concern basis. In considering the going concern basis, the Directors have considered the previously mentioned principal risks and uncertainties, as well as the Group's current trading performance and updated cashflow forecasts. The Directors have also considered the financial resources available to the Group, with net current assets of £461.5m at 31 December 2024 (compared to £485.7m at 30 June 2024), including £233.2m cash and cash equivalents and bank deposits at 31 December 2024.

We have updated our reverse stress testing to identify what would need to happen in the period to 28 February 2026 for the Group to deplete its cash and cash equivalents and bank deposit balances. This identified a trading level so low (significantly below FY2024 revenue) that the Directors feel that the events that could trigger this would be remote. The Directors also concluded that a one-off cash outflow that would exhaust the Group's cash and cash equivalents and bank deposit balances in the assessment period was also remote.

Based on this assessment, the Directors have a reasonable expectation that the Group will be able to continue in operation and meet its liabilities as they fall due over the period to 28 February 2026.

 

2.         Revenue disaggregation and segmental analysis

 

Within the Manufacturing technologies segment there are multiple product offerings with similar economic characteristics, similar production processes and similar customer bases. Our Manufacturing technologies segment consists of Industrial Metrology, Position Measurement and Additive Manufacturing product groups. Analytical instruments and medical devices segment comprises our Spectroscopy and Neurological product lines. More details of the Group's products and services are given in the Strategic Report of the 2024 Annual Report.

In normal trading conditions, whilst future revenue is difficult to predict given that the Group's outstanding order book is typically less than three months' worth of revenue value, larger consumer electronics orders in the APAC region within the Manufacturing technologies segment typically fall in the first or last quarter of the financial year. In addition, the Group typically experiences lower demand in August and December, and so revenue and operating profits are typically lower in the first half of the year. This information is provided to allow for a better understanding of the results, and management do not believe that the business is 'highly seasonal' in accordance with IAS 34.

 

 

 

Manufacturing technologies

Analytical instruments and medical devices

 

 

Total

6 months to 31 December 2024

£'000

£'000

£'000

Revenue

322,625

18,777

341,402

Depreciation, amortisation and impairment

13,780

892

14,672

Operating profit

52,774

(1,214)

51,560

Share of profits from joint ventures

1,806

-

1,806

Net financial income

-

-

4,118

Profit before tax

-

-

57,484



 

2.         Segmental information (continued)

 

 

 

Manufacturing technologies

Analytical instruments and medical devices

 

 

Total

6 months to 31 December 2023

£'000

£'000

£'000

Revenue

311,069

19,420

330,489

Depreciation, amortisation and impairment

13,391

783

14,174

Operating profit

45,953

1,241

47,194

Share of profits from joint ventures

2,530

-

2,530

Net financial income/(expense)

-

-

6,817

Profit before tax

-

-

56,541





Year ended 30 June 2024




Revenue

648,063

43,238

691,301

Depreciation, amortisation and impairment

31,374

1,454

32,828

Operating profit

103,181

5,486

108,667

Share of profits from joint ventures

3,880

-

3,880

Net financial income/(expense)

-

-

10,047

Profit before tax

-

-

122,594

 

There is no allocation of assets and liabilities to segments identified above. Depreciation, amortisation and impairments are allocated to segments on the basis of the level of activity.

The following table shows the disaggregation of Group revenue by category:


6 months to

31 December

2024

£'000

6 months to

31 December

2023

£'000

Year ended

30 June

2024

£'000

Goods, capital equipment and installation

 306,441

 300,745

624,491

Aftermarket services

 34,961

 29,744

66,810

Total Group revenue

 341,402

 330,489

691,301

Aftermarket services include repairs, maintenance and servicing, programming, training, extended warranties, and software licences and maintenance. There is no significant difference between our two reporting segments as to their split of revenue by type.

The following table shows the analysis of revenue by geographical market:


6 months to

31 December

2024

£'000

6 months to

31 December

2023

£'000

Year ended

30 June

2024

£'000

APAC

           161,366

 161,199

318,836

UK (country of domicile)

             18,825

 17,173

37,956

EMEA, excluding UK

             83,486

 80,035

170,077

EMEA

           102,311

 97,208

208,033

Americas

             77,725

 72,082

164,432

Total Group revenue

           341,402

 330,489

691,301

Revenue in the previous table has been allocated to regions based on the geographical location of the customer. Countries with individually significant revenue figures in the context of the Group were:

 


6 months to

31 December

2024

£'000

6 months to

31 December

2023

£'000

Year ended

30 June

2024

£'000

China

87,976

 90,369

177,155

USA

67,345

 60,707

138,836

Japan

25,036

 26,366

54,572

Germany

28,175

 25,646

49,329

 

There was no revenue from transactions with a single external customer amounting to 10% or more of the Group's total revenue.

3.         Cost of sales

 

 

 

6 months to

31 December

2024

£'000

6 months to

31 December

2023

£'000

Year ended

30 June

2024

£'000


 



Production costs

 131,486

 130,473

        269,562

Research and development expenditure

33,781

 32,156

          71,060

Other engineering expenditure

21,758

 19,390

          35,723

Gross engineering expenditure

55,539

 51,546

        106,783

Development expenditure capitalised (net of amortisation)

(1,855)

(2,065)

(4,287)

Development expenditure impaired

 -  

 -  

            3,299

Research and development tax credit

(3,110)

(4,050)

(7,699)

Total engineering costs

 50,574

 45,431

          98,096

Total cost of sales

182,060

 175,904

        367,658

 

 

4.         Financial income and expenses

 

 

 

 

6 months to

31 December

2024

£'000

6 months to

31 December

2023

£'000

Year ended

30 June

2024

£'000

Financial income




Bank interest receivable

 6,091

 4,745

9,110

Interest on pension schemes' assets

248

 1,439

2,908

Fair value gains from one-month forward currency contracts

-

 380

318

Currency gains

-

 604

 -  

Total financial income

6,339

 7,168

12,336

Financial expenses




Currency losses

1,448  

 -  

1,645

Lease interest

348

 214

537

Fair value losses from one-month forward currency contracts

264

-

-

Interest payable on amounts owed to joint ventures

74

-

55

Interest payable on borrowings

18

 24

36

Other interest payable

69

 113

16

Total financial expenses

2,221

 351

2,289

 

Currency losses relate to revaluations of foreign currency-denominated balances using latest reporting currency exchange rates. The losses recognised in FY2025 H1 largely related to an appreciation of Sterling relative to the Mexican Peso affecting intragroup balances in the Company.  We converted this intra group balance to share capital towards the end of H1 such that we are no longer exposed to the related currency risk.

 

Rolling one-month forward currency contracts are used to offset currency movements on certain intragroup balances, with fair value gains and losses being recognised in financial income or expenses.

 

 

5.         Taxation

 

The income tax expense in the Consolidated income statement has been estimated at a rate of 20.1% (H1 FY2024: 20.1%), based on management's best estimate of the full year effective tax rates by geographical unit, applied to half-year profits. This compares to 21.0% in FY2024.

 

 

6.         Earnings per share

 

The earnings per share for the six months ended 31 December 2024 is calculated on earnings of £45,929,000 (31 December 2023: £45,177,000) and on 72,729,059 shares (31 December 2023: 72,719,565 shares), being the number of shares in issue during the period. This excludes 59,484 shares (31 December 2023: 68,978 shares) held by the Renishaw Employee Benefit Trust.

 

 

 

 

7.         Dividends

 

 

Dividends paid during the period were:

 

6 months to

31 December

2023

£'000

Year ended

30 June

2024

£'000




FY2024 final dividend paid of 59.4p per share (FY2023: 59.4p)

 43,195

43,195

FY2024 Interim dividend paid of 16.8p per share (FY2023: 16.8p)

-

 12,217

Total dividends paid during the period

 43,205

 43,195

 55,412

 

All shareholders on the register on 7 March 2025 will be paid an interim dividend of 16.8p net per share on 8 April 2025, resulting in a dividend payable of £12,218,000.

 

 

8.         Property, plant and equipment

 

 

 

 

Freehold

land and

buildings

 

Plant and

equipment

 

Motor

vehicles

Assets in the

course of construction

 

 

Total

 

£'000

£'000

£'000

£'000

£'000

Cost






At 1 July 2024

255,536

278,189

6,099

56,593

 596,417

Additions

81

11,174

712

 11,385

23,352

Transfers

2,284

6,430

 -  

(8,714)

 -  

Disposals

(527)  

(2,936)

(564)

 -  

(4,027)

Currency adjustment

(1,550)

 (1,248)

 (83)

 -  

 (2,881)







At 31 December 2024

255,824

 291,609

6,164

 59,264

 612,861







Depreciation






At 1 July 2024

 49,460

216,838

 5,079

 -  

271,377

Charge for the period

2,548

7,221

153

 -  

9,922

Disposals

(251)  

(1,551)

(416)

 -  

(2,218)

Currency adjustment

(361) 

(792)

(64)

 -  

(1,217)







At 31 December 2024

51,396

221,716

4,752

 -  

 277,864







Net book value

 

 

 

 

 

At 31 December 2024

204,428

69,893

1,412

59,264

 334,997

At 30 June 2024

 206,076

 61,351

 1,020

 56,593

 325,040

 

Additions to assets in the course of construction of £11,385,000 (31 December 2023: £35,939,000) comprise £3,752,000 (31 December 2023: £25,685,000) for freehold land and buildings and £7,633,000 (31 December 2023: £10,254,000) for plant and equipment. At the end of the period, assets in the course of construction, not yet transferred, of £59,264,000 (31 December 2023: £83,553,000) comprise £35,969,000 (31 December 2023: £62,777,000) for freehold land and buildings and £23,295,000 (31 December 2023: £20,776,000) for plant and equipment. This mostly relates to the expansion of our manufacturing facility in Miskin, Wales.

 

 

 

 

 

 

 

 

 

 

 

 

 

 

9.         Intangible assets

 


 

Goodwill

 

Internally

generated

development costs

Software licences

Intellectual property and other intangible assets

 

 

 

Total


£'000

£'000

£'000

£'000

£'000

Cost




 


At 1 July 2024

 20,258

 187,941

 12,197

 4,864

 220,301

Additions

-

4,079

226

-

4,305

Currency adjustment

(5)

-

(39)

(10)

(54)







At 31 December 2024

20,253

192,020

12,384

4,854

229,511





 


Amortisation




 


At 1 July 2024

 9,028

 154,531

 11,751

 2,607

 177,917

Charge for the period

-

2,224

86

84

2,394

Currency adjustment

-

-

(34)

10

(24)







At 31 December 2024

9,028

156,755

11,803

2,701

180,287





 


Net book value

 

 

 

 

 

At 31 December 2024

11,225

35,265

581

2,153

49,224

At 30 June 2024

 11,230

33,410

 446

 2,257

 47,343

 

As detailed in the 2024 Annual Report, the key assumption in determining the value-in-use of intangible assets are sales forecasts. Latest sales forecasts, and other factors which may impact the business plans, for relevant cash generating units have been reviewed for indicators of impairment on 31 December 2024. This includes an assessment of our discount rate based on prevailing market assumptions on 31 December 2024, which has increased to 10.9% based on a higher risk-free rate (31 December 2023: 10.7%). As a result of the review, no impairments have been recognised in the six months to 31 December 2024 (31 December 2023: nil).

 

 

10.        Financial instruments

 

There is no significant difference between the fair value of financial assets and financial liabilities and their book value in the Consolidated balance sheet. All financial assets and liabilities are held at amortised cost, apart from the forward exchange contracts which are held at fair value, with changes going through the Consolidated income statement unless subject to hedge accounting. The fair values of the forward exchange contracts have been calculated by a third-party expert, discounting estimated future cash flows on the basis of market expectations of future exchange rates, representing level 2 in the IFRS 13 fair value hierarchy. There were no transfers between levels during any period disclosed.

 

Credit risk

The Group carries a credit risk relating to non-payment of trade receivables by its customers. The Group establishes an allowance for impairment in respect of trade receivables where recoverability is considered doubtful. In the six months to 31 December 2024, the Group has generally not experienced a deterioration in debtor repayments nor in the assumptions used in calculating allowances for expected credit losses. At 31 December 2024, total expected credit losses amounted to £4,756,000, being 4.1% of gross trade receivables, compared with £4,480,000 at 30 June 2024, being 3.2% of gross trade receivables.

 

Liquidity risk

The Group's approach to managing liquidity is to ensure, as far as possible, that we will always have sufficient liquidity to meet our liabilities when due, without incurring unacceptable losses or risking damage to the Group's reputation. We use monthly cash flow forecasts on a rolling 12-month basis to monitor cash requirements. Net cash and bank deposits on 31 December 2024 totalled £233,161,000, compared with £217,835,000 at 30 June 2024. This increase included a dividend payment of £43,205,000 and cash generation from operating activities of £76,241,000 during the period. In consideration of this, the Group remains in a strong liquidity position.

 

 

 

 

 

10.        Financial instruments (continued)

 

Market risk

The Group continues to mitigate market risk on cash flows using USD, EUR and JPY forward currency contracts. At 31 December 2024 the total nominal value of USD, EUR and JPY forward contracts held for cash flow hedging purposes was £450,775,855 (31 December 2023: £414,873,000). At 31 December 2024, there were no remaining USD, EUR or JPY forward contracts ineffective for cash flow hedging and yet to mature (31 December 2023: nil), with no additional forward contracts becoming ineffective for hedge accounting purposes in the six months to 31 December 2024. A decrease of 10% in the highly probable revenue forecasts of Renishaw plc and Renishaw UK Sales Limited, being the hedged item, would result in no forward contracts becoming ineffective on 31 December 2024.

 

 

11.        Employee benefits

 

The net surplus of the Group's defined benefit pension schemes, on an IAS 19 basis, has increased from a £10,845,000 asset at 30 June 2024 to a £11,410,000 asset at 31 December 2024. This mostly relates to a reduction in liabilities within the Irish scheme due to strong asset growth. During FY2024, the Trustee of the UK scheme undertook a buy-in and insured around 99% of the UK scheme's liabilities by purchasing an insurance policy. This contract was effective from 19 October 2023 and the value of the contract is recognised as a UK scheme asset. The buy-in eliminates investment return, longevity, inflation and funding risks in respect of those liabilities covered. Changes to other key assumptions from 30 June 2024 to 31 December 2024 have not had a material effect on the schemes.

 

Benefits in the UK Scheme are subject to a DC underpin at the point of retirement or transfer out. Historically, this has been allowed for in the accounts in a consistent manner to current administrative practice and the triennial funding valuations. During the buy-in process, it was identified that the drafting of the DC underpin in the UK Scheme Rules may require that the DC underpin is applied in a manner which is different to the administrative practice which has been applied. The Trustee and Company are currently seeking legal clarification and advice on this issue, with the intention of correcting the Rules to match administrative practice. No allowance for this matter has been made in 31 December 2024, as management continue to assess it to be unlikely that there will be an increase in liabilities, and due to the uncertainty of legal treatment and therefore any potential impact on liabilities.

 

In June 2023, the High Court ruled that certain historic amendments made to the rules of the Virgin Media pension scheme were invalid without the scheme's actuary having provided the associated Section 37 certificates. This judgment was upheld by the Court of Appeal in July 2024, which has implications on other schemes that were contracted-out on a salary-related basis, and made amendments between April 1997 and April 2016. The UK scheme was contracted out until 5 April 2007 and amendments were made during the relevant period and as such the ruling could have implications for the UK scheme. Since June 2024, the Company and the Trustees have commenced a review of all amending documents between 6 April 1997 and 5 April 2016 for the scheme to determine whether proper procedures were undertaken at the time of the amendments by the Trustees, actuaries and administrators. At the date of approving these interim financial statements, the possible implications, if any, for the UK scheme not having all Section 37 certificates have not been investigated in detail. The Trustee and Company continue to seek legal advice on this matter and will act appropriately. Accordingly, no amendments for this matter have been included in the IAS 19 actuarial valuation as the impact, if any, cannot be reliably assessed.

 

 

12.        Alternative performance measures

 

In accordance with Renishaw's Alternative Performance Measures (APMs) policy and ESMA Guidelines on Alternative Performance Measures (2015), this section defines non-IFRS measures that we believe give readers additional useful and comparable views of our underlying performance. We continue to report Revenue at constant exchange rates, Adjusted profit before tax, Adjusted earnings per share, Adjusted operating profit, Adjusted operating profit at constant exchange rates, Adjusted cash flow conversion from operating activities, and Return on invested capital.

 

Revenue at constant exchange rates is defined as revenue recalculated using the same rates as were applicable to the previous year and excluding forward contract gains and losses.

 

 

 

 

 



 

12. Alternative performance measures (continued)

 

Revenue at constant exchange rates

 

 

6 months to 31 December 2024

6 months to 31 December 2023

 

 

£'000

£'000

 

 

 


Statutory revenue as reported

 

 341,402

 330,489

Adjustment for forward contract (gains)/losses

 

 (12,959)

 1,853

Adjustment to restate at previous year exchange rates

 

 11,342

-

Revenue at constant exchange rates

 

339,785

332,342

Year-on-year revenue growth at constant exchange rates

 

2%

-

 

For this period and the comparable period there is no difference between 'Statutory' and 'Adjusted' for our alternative performance measures, being Adjusted profit before tax, Adjusted earnings per share and Adjusted operating profit, including segmental operating profit.

 

Operating profit at constant exchange rates is defined as Operating profit recalculated using the same rates as applied to the previous year and excluding forward contract gains and losses.

 

Operating profit at constant exchange rates

 

 

6 months to 31 December 2024

6 months to 31 December 2023

 

 

£'000

£'000

 

 

 


Operating profit

 

51,560

47,194

Adjustment for forward contract (gains)/losses

 

(12,959)

1,853

Adjustment to restate current year at previous year exchange rates

 

8,042

-

Operating profit at constant exchange rates

 

46,643

49,047

Year-on-year Operating profit reduction at constant exchange rates

 

-4.9%


 

Adjusted cash flow conversion from operating activities is calculated as Adjusted cash flow from operating activities as a proportion of Adjusted operating profit. This is useful for the Board to measure how efficient we are at converting operating profit into cash.

 

Adjusted cash flow conversion from operating activities

 

6 months to 31 December 2024

6 months to 31 December 2023

Year ended 30 June 2024

 

£'000

£'000

£'000

Cash flow from operating activities

76,241

55,570

124,079

Income taxes paid

(1,815)

12,191

21,752

Purchase of property, plant and equipment and intangible assets

(25,746)

(45,015)

(74,774)

Proceeds from sale of property, plant and equipment and intangible assets

2,814

200

4,475

Adjusted cash flow from operating activities

51,494

22,946

75,532

Adjusted cash flow conversion from operating activities

99.9%

48.6%

69.5%

 

Return on invested capital is the profit after tax before bank interest receivable as a percentage of the Average invested capital in the year. This is useful for the Board to measure our efficiency in allocating capital to profitable activities.

 

Profit after tax before bank interest receivable is calculated as follows:

 

6 months to 31 December 2024

6 months to 31 December 2023

Year ended 30 June 2024

 

£'000

£'000

£'000

Profit after tax

45,929

45,177

96,889

Bank interest receivable (net of tax)

(4,568)

(3,559)

(6,832)

Profit after tax before bank interest received

41,361

41,618

90,057

 

Profit after tax before bank interest received for the 12-months to 31 December 2024 was £89.8m.



 

12.        Alternative performance measures (continued)

 

Return on invested capital (ROIC):

6 months to 31 December 2024

6 months to 31 December 2023

Year ended 30 June 2024

Year ended 30 June 2023

 

£'000

£'000

£'000

£'000

Total non-current assets

479,609

452,295

464,765

470,430

Total current assets

564,208

535,381

586,618

573,107

Total current liabilities

(102,677)

(86,768)

(100,948)

(102,320)

Less cash and cash equivalent

(90,161)

(59,258)

(122,293)

(81,388)

Less bank deposits

(143,000)

(119,000)

(95,542)

(125,000)

Invested capital

707,979

722,650

732,600

734,829

Average invested capital

715,314

-

733,715

-

Return on invested capital

12.6%

-

12.3%

-

 

Average invested capital in the year is the average of the invested capital at the beginning of the reporting period and at the end of the reporting period.

 

 

13.        Related party transactions and events subsequent to the end of the reporting period

 

Transactions between the Company and its subsidiaries, which are related parties, have been eliminated on consolidation and are not disclosed in this note. Full details of the Group's other related party relationships, transactions and balances are given in the Group's Annual Report for the year ended 30 June 2024.

 

During FY2024, Renishaw International Limited ('RIL') entered into a 14-day notice deposit agreement with RLS Merilna tehnika d.o.o. ('RLS'). Interest is payable by RIL to RLS at a market rate on a monthly basis. As at 31 December 2024, according to this agreement, the amount RIL had received was EUR 14.0m (£11.6m equivalent), an increase from EUR 10.0m (£8.5m equivalent) at 30 June 2024. The amounts are recognised as 'amounts payable to joint venture' in the Consolidated balance sheet.

 

No other related party transactions have taken place in the first six months of FY2025, or events subsequent to the end of the reporting period, that have materially affected the financial position or the performance of the Group during that period.

 



 

14.        Responsibility statement

 

The condensed set of financial statements is the responsibility of, and has been approved by, the Directors. We confirm that to the best of our knowledge:

 

-       As required by DTR 4.2 of the Disclosure Rules and Transparency Rules, the condensed set of financial statements, which has been prepared in accordance with the applicable set of accounting standards, gives a true and fair view of the assets, liabilities, financial position and profit or loss of the Company and the undertakings included in the consolidation as a whole. The Interim report has been prepared in accordance with IAS 34, 'Interim Financial Reporting', as issued by the International Accounting Standards Board and as adopted by the UK.

 

-       The Interim report includes a fair review of the information required by:

(a) DTR 4.2.7 of the Disclosure Rules and Transparency Rules, being an indication of important events that have occurred during the first six months of the financial year and their impact on the condensed set of financial statements; and a description of the principal risks and uncertainties for the remaining six months of the year; and

(b) DTR 4.2.8 of the Disclosure Rules and Transparency Rules, being related party transactions that have taken place in the first six months of the current financial year and that have materially affected the financial position or performance of the entity during that period; and any changes in the related party transactions described in the last Annual Report that could do so.

 

 

On behalf of the Board

 

Allen Roberts FCA

Group Finance Director

12 February 2025

 

 

Registered office:         Renishaw plc, New Mills, Wotton-under-Edge, Gloucestershire GL12 8JR, U.K.

 

Registered number: 

01106260

Company Secretary:

companysecretary@renishaw.com

Telephone:

+44 1453 524524

Website:                

www.renishaw.com

 



This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
IR GPURPPUPAPGP
Renishaw (LSE:RSW)
Historical Stock Chart
From Feb 2025 to Mar 2025 Click Here for more Renishaw Charts.
Renishaw (LSE:RSW)
Historical Stock Chart
From Mar 2024 to Mar 2025 Click Here for more Renishaw Charts.